245 First Street, 4th Floor
About Magenta TherapeuticsMagenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients. Over the past 50 years, stem cell transplantation has been used in more than 1M patients worldwide. It is currently the only treatment with the potential to cure some of the most devastating hematologic cancers and autoimmune diseases. Despite the increased use and clinical advancements over the past several decades, stem cell transplant remains a high-risk last-resort therapeutic option due to the toxicity and potential long-term side effects.
Founder and CEO: Jason Gardner
COO: Bastiano Sanna
CSO: Michael Cooke
VP, Head of Business Development: Christina Isacson
Please click here for Magenta's job opportunities.
Please click here for Magenta's science.
43 articles with Magenta Therapeutics
Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs Demonstrating Potent Stem Cell Depletion and Anti-Leukemia Survival Benefit
Magenta Therapeutics today announced that the Company presented preclinical research on its targeted conditioning programs at the 60th annual meeting of the American Society of Hematology (ASH).
Magenta Therapeutics Presents New Data from Phase 2 Study of MGTA-456 Cell Therapy in Patients with Inherited Metabolic Disorders
All five patients with inherited metabolic disorders (IMDs) treated with MGTA-456 in ongoing Phase 2 study met the primary endpoint of successful engraftment
Magenta Therapeutics Presents New Preclinical Data on MGTA-145 Stem Cell Mobilization Product Candidate
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that the Company highlighted new preclinical research on its MGTA-145 product candidate for stem cell mobilization in an oral presentation at the 60th annual meeting of the American Society of Hematology (ASH)
Live webcast of an investor and analyst event at 8:30 p.m. PST (11:30 p.m. EST) on Sunday, December 2, 2018, during the American Society of Hematology (ASH) Annual Meeting.
Effective January 1, 2019
Nine clinical and preclinical abstracts accepted for presentation at American Society of Hematology (ASH) annual meeting
Heidelberg Pharma Announces Several Presentations of Research Results on ATAC Technology at the ASH Annual Meeting 2018
- Partner MD Anderson Cancer Center will present preclinical data on HDP-101 for effective 17p deletion in multiple myeloma in an oral presentation
Magenta Therapeutics Announces Acceptance of Nine Abstracts Covering Clinical and Preclinical Data at ASH, Representing Progress across the Portfolio of Conditioning, Stem Cell Mobilization and Expansion Programs
Non-genotoxic antibody drug conjugates (ADCs) potently depleted human stem cells in five abstracts on targeted conditioning programs and demonstrated survival benefit in patient-derived leukemia models
Partner Magenta Therapeutics Exercises Option To Further Develop a Target Molecule as Antibody Targeted Amanitin Conjugate
Heidelberg Pharma AG today announced that its partner Magenta Therapeutics (NASDAQ: MGTA), Cambridge, MA, USA, exercises its option to further develop a target molecule, and will now continue the development of an Antibody Targeted Amanitin Conjugate based on the target molecule within an exclusive licensing.
The Russell 3000 index includes the 3,000 largest U.S. companies by market capitalization.
Transplanted first patient with MGTA-456 in Phase 2 study in inherited metabolic disorders
Magenta Therapeutics(NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that the Company is scheduled to present at the 2018 Wedbush PacGrow Healthcare Conference on Tuesday, August 14th, at 9:10 a.m. ET.
Convelo Therapeutics to Develop New Regenerative Medicines for Neurological Disease Characterized by Loss of Myelin
Convelo Therapeutics, Inc. announced today that it has launched from stealth mode with a mission to discover and develop a new class of medicines that regenerate the protective myelin coating around nerve cells that is lost in a wide array of neurological diseases, including multiple sclerosis (MS).
It’s been a pretty good year for mergers and acquisitions in the biopharma industry. But the landscape for IPOs has been excellent as well, particularly in Massachusetts, which has recorded 13 IPOs since the beginning of the year.
6/22/2018Autolus Therapeutics snagged $150 million from its initial public offering, about $25 million more than the company initially expected when it began its roadshow effort earlier this month.
It’s a super-busy week for biotech initial public offerings (IPOs) with six companies raking in a total of around $568 million.
Pricing of its initial public offering of 6,666,667 shares of its common stock at a price to the public of $15.00 per share, for total gross proceeds of approximately $100,000,000
Magenta Therapeutics is a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients
6/8/2018Three clinical-stage biotechnology companies announced initial public offerings (IPOs) today. Here’s a summary.
5/29/2018It’s been a busy month for IPOs. Numerous biotech companies announced their intentions to publicly list their stock on an exchange in the U.S. or abroad in order to gain new funding to advance developmental programs.